Stock News

A 51 per cent stake in a Polish drone company remains a non-binding proposal, while the registered share sale is expected to close Sept. 24.

The Fort Worth lease calls for staged production in late 2027; Hammond expects to fund initial equipment and commissioning with cash and credit lines.

Cumulative repurchases reached about 14.5 per cent of the original share base; Silvia did not disclose what the latest purchases cost.

NexGold reports 3,603 metres of diamond drilling in ten Goldlund holes, with assays from Zone 4, Zone 50 and interzone intervals.

The second batch is due in Mississippi in October after an Oklahoma installation planned for Sept. 30.

The Health Canada-authorized depression study plans to enroll up to 200 people, while the batch also serves Australian clinics.

Solidcore may earn stakes in five exploration areas, while a US$3 million royalty payment remains pending.

OASIZ 301 met its systemic disease measure, but Amgen did not disclose the treatment gap; a second Phase 3 study is due to finish this year.

The addition gives Curaleaf a second Canadian benchmark, but its Sept. 23 release does not quantify any resulting fund purchases.

Base-case after-tax NPV is US$1.5 billion at US$4.75 a pound copper; first cathode is targeted for 2029.

Panorama's week-12 result came with widespread treatment guesses; Definium plans an FDA meeting in the fourth quarter.

The adult GEP-NET radiopharmaceutical is therapeutically equivalent to Lutathera, but Lantheus has not announced its launch date or price.

The 57-patient study missed its Week 12 skin disease endpoint, leaving five other autoimmune indications on Immunovant's development calendar.

Sefaxersen beat placebo on a week-37 urine protein measure, but Roche and Ionis have not disclosed the size of the effect or safety rates.

The Nasdaq company carries a market value of US$6.7 million and has now put about US$60 million of Pennsylvania land under contract.

Freeport and Hudbay shares rise as Chinese physical premiums climb and SMM reports a weekly inventory draw of 14,500 tonnes.

Vanguard's Extended Market Index Fund, which held US$95.4 billion on Aug. 31, tracks one of the two benchmarks that took the shares in.

GROW Group will distribute the Kincardine-grown flower in Britain under Canopy's Spectrum Therapeutics medical brand.

The Under New Ownership campaign went up on Sept. 21, and Tilray says it has reopened 16 BrewDog bars since the takeover closed.

One metre of the intercept assayed 384.01 grams per tonne, and Agnico Eagle now holds 10.45 per cent of the Quebec explorer.

The company spent US$174 million buying back its Stretch preferred stock over the same week, more than twice what it put into bitcoin.

The contract obliges New Era to post a letter of credit of US$116 million within 15 business days of the Sept. 18 signing.

Canada Growth Fund came out of the sale holding 19.9 per cent of the developer, whose Marathon copper-palladium mine starts early works in the fourth quarter.

The Molecular and Clinical Genetics Panel votes Wednesday on whether the multi-cancer blood test is safe, effective and worth its risks.

SynCardia's Total Artificial Heart serves as a temporary solution while patients wait for donors

The leading firm is expecting to raise US$900M from its long-awaited public launch

ChangXin Memory Technologies is now worth over US$475 billion

The firm's assessments have an influential track record

It just surged above 68,000 for the first time

The oncology and biotech firm has secured approximately US$22.5 million

The company has been making a comeback since its 2023 bankruptcy

Compliance issues, low trading volume and other problems prompted the move

The financial institution has given the drug developer a Buy rating a US$12 share target

The gold producer has gone six years without a lost time incident at the Nevada mine site

South Korea's Kospi Index was impacted worst Monday, declining by more than 6%

Apollo lost US$12 billion in market value over associating with the sex offender

urban-gro has been facing Nasdaq compliance issues, declining revenue and a dwindling stock price

Investors were highly intrigued by their successful studies

The Nasdaq Composite Index saw monetary growth exceeding 20%

The quadruped surveillance bot creator went public on Dec. 10